| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.6M | 0.00% | 459.00K | −16% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Yednock TedOfficer | Conversion of Exercise of derivative security at price 1.85 per share. | 30.6K | $56.70K |
| May 10, 2026 | Carson William H.Director | Purchase at price 5.78 per share. | 8K | $46.24K |
| Apr 9, 2026 | Carson William H.Director | Purchase at price 6.20 per share. | 8K | $49.60K |
| Mar 9, 2026 | Carson William H.Director | Purchase at price 5.67 per share. | 8K | $45.36K |
| Mar 1, 2026 | Lew JenniferChief Financial Officer | Sale at price 5.42 per share. | 5.6K | $30.16K |
| Mar 1, 2026 | Dananberg JamieOfficer | Sale at price 5.43 per share. | 5.8K | $31.60K |
| Mar 1, 2026 | Overdorf MichaelOfficer | Sale at price 5.42 per share. | 4.3K | $23.52K |
| Mar 1, 2026 | Yednock TedOfficer | Sale at price 5.42 per share. | 5.6K | $30.17K |
| Mar 1, 2026 | Artis Dean Richard Ph.D.Officer | Sale at price 5.43 per share. | 5.9K | $32.00K |
| Feb 18, 2026 | Yednock TedOfficer | Stock Award(Grant) at price 0.00 per share. | 62.5K | — |
| Feb 18, 2026 | Artis Dean Richard Ph.D.Officer | Stock Award(Grant) at price 0.00 per share. | 62.5K | — |
| Feb 18, 2026 | Lew JenniferChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 62.5K | — |
| Feb 18, 2026 | Dananberg JamieOfficer | Stock Award(Grant) at price 0.00 per share. | 56.3K | — |
| Feb 18, 2026 | Overdorf MichaelOfficer | Stock Award(Grant) at price 0.00 per share. | 62.5K | — |
| Feb 17, 2026 | Lew JenniferChief Financial Officer | Sale at price 5.11 per share. | 7.9K | $40.12K |
| Feb 17, 2026 | Dananberg JamieOfficer | Sale at price 5.10 per share. | 5.3K | $26.98K |
| Feb 17, 2026 | Overdorf MichaelOfficer | Sale at price 5.10 per share. | 6.2K | $31.75K |
| Feb 17, 2026 | Yednock TedChief Technology Officer | Sale at price 5.11 per share. | 7.9K | $40.15K |
| Feb 17, 2026 | Artis Dean Richard Ph.D.Officer | Sale at price 5.10 per share. | 5.3K | $26.98K |
| Dec 29, 2025 | Carson William H.Director | Purchase at price 5.02 per share. | 4.1K | $20.66K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 24.3 | -10.3 | -1.1 | 6.0 | -7.7 | 5.4 | -10.8 | -3.0 | -14.4 | -9.5 | −23.7% | ||
| 2025 | -25.1 | -31.2 | -26.9 | -3.6 | 9.7 | 17.6 | 0.0 | -14.2 | 48.1 | 3.6 | 42.4 | 11.6 | −2.1% |
| 2024 | -8.5 | 34.1 | 28.7 | -36.5 | 6.2 | 1.4 | 30.8 | -11.1 | 3.9 | 23.6 | -26.4 | -4.8 | +13.0% |
| 2023 | 38.1 | -25.4 | -27.8 | 37.8 | -43.6 | 17.7 | -2.0 | -20.3 | -14.2 | -3.8 | 9.7 | 82.3 | −12.2% |
| 2022 | -34.7 | -35.3 | -43.8 | -6.6 | 23.1 | 20.1 | 32.9 | 17.4 | 5.1 | -22.7 | 13.8 | -5.0 | −55.0% |
| 2021 | -12.1 | 32.3 | -4.4 | -28.4 | 6.0 | 6.6 | -6.4 | -22.4 | 13.8 | -12.4 | -0.1 | -29.5 | −54.1% |
| 2020 | 35.3 | 22.5 | -31.2 | 16.3 | 3.4 | +37.3% |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Buy / hold / sell counts
No member of Congress has disclosed a ANNX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades